Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

NCT01170650
completedphase_2

Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

NCT01577654
completedphase_2

Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)

NCT00722592
completedphase_1

Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

NCT00852189

Clinical Trials (4)

Showing 4 of 4 trials
NCT01170650Phase 3

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Terminated
NCT01577654Phase 2

Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

Completed
NCT00722592Phase 2

Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)

Completed
NCT00852189Phase 1

Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4